Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor

BMC Microbiology

Chinnambedu N Paramasivan¹  Perumal Venkatesan³  Ramaian Santhaseela Anand⁴  Sulochana Somasundaram² 

[1] Foundation for Innovative New Diagnostics, Flat No. 6-14 (excluding No. 7), 9th floor, Vijaya Building, 17-Barakhamba Road, New Delhi 110 001, India;Department of Biotechnology, Sri Venkateswara College of Engineering, Sriperumbudur, India;National Institute for Research in Tuberculosis, Chennai, India;Centre for Biotechnology, Anna University, Chennai, India

关键词: PA-824;    Ddn;    Docking;    Anaerobic activity;    Mycobacterium tuberculosis;    Bactericidal activity;   

Others  :  1143002
DOI  :  10.1186/1471-2180-13-218

 received in 2013-02-12, accepted in 2013-09-27,  发布年份 2013

【 摘 要 】

Background

The resurgence of multi-drug resistant tuberculosis (MDR-TB) and HIV associated tuberculosis (TB) are of serious global concern. To contain this situation, new anti-tuberculosis drugs and reduced treatment regimens are imperative. Recently, a nitroimidazole, PA-824, has been shown to be active against both replicating and non-replicating bacteria. It is activated by the enzyme Deazaflavin-dependent nitroreductase (Ddn) present in Mycobacterium tuberculosis which catalyzes the reduction of PA-824, resulting in the release of lethal reactive nitrogen species (RNS) within the bacteria. In this context, PA-824 was analyzed for its activity against latent tuberculosis under anaerobic conditions and compared with rifampicin (RIF) and pyrazinamide (PZA). Recent mutagenesis studies have identified A76E mutation which affects the above mentioned catalysis and leads to PA-824 resistance. Hence, novel analogues which could cope up with their binding to mutant Ddn receptor were also identified through this study.

Results

PA-824 at an optimum concentration of 12.5 μg/ml showed enhanced bactericidal activity, resulting in 0 CFU/ml growth when compared to RIF and PZA at normal pH and anaerobic condition. Further docking studies revealed that a combinatorial structure of PA-824 conjugated with moxifloxacin (ligand 8) has the highest binding affinity with the wild type and mutant Ddn receptor.

Conclusions

PA-824 has been demonstrated to have better activity under anaerobic condition at 12.5 μg/ml, indicating an optimized dose that is required for overcoming the detoxifying mechanisms of M. tuberculosis and inducing its death. Further, the development of resistance through A76E mutation could be overcome through the in silico evolved ligand 8.

【 授权许可】

   
2013 Somasundaram et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Global Tuberculosis Report: Global Tuberculosis Report. 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf webcite
• [2]Barry CE III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
• [3]Boshoff HIM, Barry CE III: Tuberculosis—metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005, 3:70-80.
• [4]Sharma SK, Mohan A: Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 2006, 130:261-272.
• [5]Kantardjieff K, Rupp B: Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr Pharm Des 2004, 10:3195-3211.
• [6]TB alliance 2012. http://new.tballiance.org/new/portfolio/html-portfolio-item.php?id=18 webcite
• [7]Diacon AH, et al.: Early bactericidal activity and pharmacokinetics of pa-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010, 54(8):3402-3407.
• [8]Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J: Bactericidal activity of the nitroimidazopyran pa-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005, 49(6):2289-2293.
• [9]Manjunatha UH, Helena B, Cynthia S, Dowd , Liang Z, Thomas J, Albert , Jason E, Norton , Lacy D, Thomas D, Siew Siew P, Clifton E, Barry : Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. PNAS 2006, 103(2):431-436.
• [10]Wayne LG, Hayes LG: An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996, 64(6):2062-2069.
• [11]Wayne LG: Synchronized replication of Mycobacterium tuberculosis. Infect Immun 1977, 17:528-530.
• [12]Trott O, Olson AJ, AutoDock Vina : Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010, 31:455-461.
• [13]Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
• [14]ACD/ChemSketch Freeware, version 10.00. Toronto, ON, Canada: Advanced Chemistry Development, Inc; 2006. http://www.acdlabs.com webcite
• [15]Schuettelkopf AW, Aalten V: DMF: PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Cryst 2004, D60:1355-1363.
• [16]Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, Boshoff HI, Choi I, Nayyar A, Lee YS, Cherian J, Niyomrattanakit P, Dick T, Manjunatha UH, Barry CE 3rd, Spraggon G, Geierstanger BH: Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Structure 2012, 20(1):101-112.
• [17]Domagala J: Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother Apr, 33(4):685-706.
• [18]Molegro molecular viewer – version 2.5.0. http://www.molegro.com/index.php webcite
• [19]Stover : A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966.
• [20]Lenaerts AJ, Veronica G, Karen S, Marietta , Christine M, Johnson , Diane K, Driscoll , Nicholas M, Tompkins , Jerry D, Rose , Robert C, Reynolds , Ian M, Orme : Preclinical testing of the Nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and In Vivo models. Antimicrob Agents Chemother 2005, 49(6):2294-2301.
• [21]Pawaria S, Lama A, Raje M, Dikshit KL: Responses of Mycobacterium tuberculosis hemoglobin promoters to in vitro and in vivo growth conditions. Appl Environ Microbiol 2008, 74:3512-3522.
• [22]Couture M, Yeh S, Wittenberg BA, Wittenberg JB, Ouellet Y, Rousseau DL, Guertin M: A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1999, 96:11223-11228.
• [23]Ouellet H, Ouellet Y, Richard C, Labarre M, Wittenberg B: Truncated hemoglobin HbN protects Mycobacterium bovis from nitric oxide. Proc Natl Acad Sci U S A 2002, 99:5902-5907.
• [24]Scott EE, Gibson QH, Olson JS: Mapping the pathways for O2 entry into and exit from myoglobin. J Biol Chem 2001, 276:5177-5188.
• [25]Tan MP, Sequeira P, Lin WW, Phong WY, Cliff P, et al.: Nitrate respiration protects hypoxic Mycobacterium tuberculosis against acid- and reactive nitrogen species stresses. PLoS One 2010, 5(10):e13356.
• [26]Milani M, Pesce A, Ouellet Y, Ascenzi P, Guertin M, Bolognesi M: Mycobacterium tuberculosis hemoglobin N displays a protein tunnel suited for O2 diffusion to the heme. EMBO J 2001, 20:3902-3909.
• [27]Milani M, Pesce A, Ouellet Y, Dewilde S, Friedman J, Ascenzi P, Guertin M, Bolognesi M: Heme-ligand tunneling in group I truncated hemoglobins. J Biol Chem 2004, 279:21520-21525.
• [28]Bidon-Chanal A, Martí MA, Crespo A, Milani M, Orozco M, Bolognesi M, Luque FJ, Estrin DA: Ligand-induced dynamical regulation of NO conversion in Mycobacterium tuberculosis truncated hemoglobin-N. Proteins 2006, 64:457-464.
• [29]Bidon-Chanal A, Martí MA, Estrin DA, Luque FJ: Dynamical regulation of ligand migration by a gate-opening molecular switch in truncated hemoglobin-N from Mycobacterium tuberculosis. J Am Chem Soc 2007, 129:6782-6788.
• [30]Daigle R, Guertin M, Lague P: Structural characterization of the tunnels of Mycobacterium tuberculosis truncated hemoglobin N from molecular dynamics simulations. Proteins: Struct Funct Bioinf 2009, 75:735-747.
• [31]Mishra S, Meuwly M: Nitric oxide dynamics in truncated hemoglobin: docking sites, migration pathways, and vibrational spectroscopy from molecular dynamics simulations. Biophys J 2009, 96(6):2105-2118.
• [32]Sarkar S, Viktor I, Korolchuk , Maurizio R, Sara I, Angeleen F, Andrea W, Moises G-A, Claudia R, Shouqing L, Benjamin R, Underwood , Guido K, Cahir J, O’Kane , David C, Rubinsztein : Complex inhibitory effects of nitric oxide on autophagy. Mol Cell 2011, 43(1):19-32.
• [33]Ham H, Sreelatha A, Orth K: Manipulation of host membranes by bacterial effectors. Nat Rev Microbiol 2011, 9:635-646.
• [34]Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL: PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011, 55:239-245.
• [35]Zhang Y, Mitchison D: The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003, 7(1):6-21.
• [36]Schwartz : Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006, 50(6):1982-1988.
• [37]Babincová : Antioxidant properties of carboxymethyl glucan: comparative analysis. J Med Food 2002, 5(2):79-83.
• [38]Wang X, Zhao X, Malik M, Drlica K: Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell deat. J Antimicrob Chemother 2010, 65(3):520-524.
• [39]Georgopapadakou NH, Bertasso A: Mechanisms of action of cephalosporin 3′-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob Agents Chemother 1993, 37(3):559-565.
• [40]Simões MF, Valente E, Gómez MJ, Anes E, Constantino L: Lipophilic pyrazinoic acid amide and ester prodrugs: stability, activation and activity against M. tuberculosis. Eur J Pharm Sci 2009, 37(3–4):257-263.
• [41]Piccaro G, Giannoni F, Filippini P, Mustazzolu A, Fattorini L: Activities of drug combinations against mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob Agents Chemother 2013, 57(3):1428-1433.
• [42]Andreas H, Diacon AH, Rodney D, Von Groote-Bidlingmaier F, Gregory S, Amour V, Donald PR: 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380(9846):986-993.